Search

Your search keyword '"Johnston, Timothy S."' showing total 2 results
Start Over Author "Johnston, Timothy S." Topic immunogenicity, vaccine
2 results on '"Johnston, Timothy S."'

1. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.

Author

Corbett KS, Gagne M, Wagner DA, O' Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham CD, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Yang ES, Wang L, Choe M, Boyoglu-Barnum S, Wei S, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, and Seder RA

Subjects
2019-nCoV Vaccine mRNA-1273 administration & dosage, Animals, Antibodies, Neutralizing blood, Antibodies, Viral analysis, Antibodies, Viral blood, Bronchoalveolar Lavage Fluid immunology, Bronchoalveolar Lavage Fluid virology, COVID-19 immunology, COVID-19 virology, COVID-19 Vaccines administration & dosage, Immunity, Mucosal, Immunization, Secondary, Macaca mulatta, Memory B Cells immunology, Nose immunology, Nose virology, RNA, Viral analysis, SARS-CoV-2 genetics, SARS-CoV-2 isolation & purification, SARS-CoV-2 physiology, T Follicular Helper Cells immunology, Th1 Cells immunology, Virus Replication, 2019-nCoV Vaccine mRNA-1273 immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, SARS-CoV-2 immunology, Vaccine Efficacy
Abstract

Neutralizing antibody responses gradually wane against several variants of concern (VOCs) after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine messenger RNA-1273 (mRNA-1273). We evaluated the immune responses in nonhuman primates that received a primary vaccination series of mRNA-1273 and were boosted about 6 months later with either homologous mRNA-1273 or heterologous mRNA-1273.β, which encompasses the spike sequence of the B.1.351 Beta variant. After boost, animals had increased neutralizing antibody responses across all VOCs, which was sustained for at least 8 weeks after boost. Nine weeks after boost, animals were challenged with the SARS-CoV-2 Beta variant. Viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, suggesting that booster vaccinations may be required to sustain immunity and protection.

Published
2021
Full Text
View/download PDF

2. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.

Author

Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, Koch M, Abiona OM, Werner AP, Moliva JI, Andrew SF, Donaldson MM, Fintzi J, Flebbe DR, Lamb E, Noe AT, Nurmukhambetova ST, Provost SJ, Cook A, Dodson A, Faudree A, Greenhouse J, Kar S, Pessaint L, Porto M, Steingrebe K, Valentin D, Zouantcha S, Bock KW, Minai M, Nagata BM, van de Wetering R, Boyoglu-Barnum S, Leung K, Shi W, Yang ES, Zhang Y, Todd JM, Wang L, Alvarado GS, Andersen H, Foulds KE, Edwards DK, Mascola JR, Moore IN, Lewis MG, Carfi A, Montefiori D, Suthar MS, McDermott A, Roederer M, Sullivan NJ, Douek DC, Graham BS, and Seder RA

Subjects
2019-nCoV Vaccine mRNA-1273, Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Antibody Affinity, Bronchoalveolar Lavage Fluid immunology, Bronchoalveolar Lavage Fluid virology, CD4-Positive T-Lymphocytes immunology, COVID-19 immunology, COVID-19 virology, Female, Immunization Schedule, Immunization, Passive, Immunization, Secondary, Immunoglobulin G immunology, Immunologic Memory, Lung immunology, Lung virology, Macaca mulatta, Male, Mesocricetus, Nasal Mucosa immunology, Nasal Mucosa virology, SARS-CoV-2 physiology, Spike Glycoprotein, Coronavirus immunology, Vaccination, Vaccine Potency, Virus Replication, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, SARS-CoV-2 immunology
Abstract

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 μg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. mRNA-1273 vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs after SARS-CoV-2 challenge in vaccinated animals and most strongly correlated with levels of anti–S antibody and neutralizing activity. Lower antibody levels were needed for reduction of viral replication in the lower airway than in the upper airway. Passive transfer of mRNA-1273–induced immunoglobulin G to naïve hamsters was sufficient to mediate protection. Thus, mRNA-1273 vaccine–induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 in NHPs.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results